NO964342L - Fremgangsmåter for behandling av sykdom under anvendelse av Sertoli-celler og allografter eller zenografter - Google Patents

Fremgangsmåter for behandling av sykdom under anvendelse av Sertoli-celler og allografter eller zenografter

Info

Publication number
NO964342L
NO964342L NO964342A NO964342A NO964342L NO 964342 L NO964342 L NO 964342L NO 964342 A NO964342 A NO 964342A NO 964342 A NO964342 A NO 964342A NO 964342 L NO964342 L NO 964342L
Authority
NO
Norway
Prior art keywords
cells
sertoli cells
zenografts
allografts
methods
Prior art date
Application number
NO964342A
Other languages
English (en)
Other versions
NO320713B1 (no
NO964342D0 (no
Inventor
Helena P Selawry
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Publication of NO964342D0 publication Critical patent/NO964342D0/no
Publication of NO964342L publication Critical patent/NO964342L/no
Publication of NO320713B1 publication Critical patent/NO320713B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0683—Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/24—Genital tract cells, non-germinal cells from gonads
    • C12N2502/246—Cells of the male genital tract, non-germinal testis cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19964342A 1994-04-13 1996-10-11 Farmasoytisk preparat som omfatter Sertoli-celler og celler som produserer en biologisk faktor, seksjonert sett med beholdere for cellene, produktartikkel som omfatter et embaleringsmateriale med Sertoli-celler og fremgangsmate for okning av utvinning og profilering av celler ex vivo. NO320713B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21169594A 1994-04-13 1994-04-13
PCT/US1995/004565 WO1995028167A1 (en) 1994-04-13 1995-04-13 Methods of treating disease using sertoli cells and allografts or xenografts

Publications (3)

Publication Number Publication Date
NO964342D0 NO964342D0 (no) 1996-10-11
NO964342L true NO964342L (no) 1996-12-13
NO320713B1 NO320713B1 (no) 2006-01-23

Family

ID=22787974

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19964342A NO320713B1 (no) 1994-04-13 1996-10-11 Farmasoytisk preparat som omfatter Sertoli-celler og celler som produserer en biologisk faktor, seksjonert sett med beholdere for cellene, produktartikkel som omfatter et embaleringsmateriale med Sertoli-celler og fremgangsmate for okning av utvinning og profilering av celler ex vivo.

Country Status (12)

Country Link
US (3) US5725854A (no)
EP (1) EP0755258B1 (no)
JP (1) JPH09512015A (no)
AT (1) ATE212230T1 (no)
AU (1) AU715177B2 (no)
CA (1) CA2187803C (no)
DE (1) DE69525151T2 (no)
DK (1) DK0755258T3 (no)
ES (1) ES2169128T3 (no)
FI (2) FI120670B (no)
NO (1) NO320713B1 (no)
WO (1) WO1995028167A1 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706062A (es) * 1995-02-08 1997-10-31 Yamanouchi Europ Bv FORMAS DE DOSIFICACION ORAL CONTENIENDO UN ANTIBIOTICO DE beta -LACTAMA.
US5830460A (en) * 1995-03-13 1998-11-03 University Of South Florida Sertoli cells as transplantation facilitator for cell transplantation
WO1996028174A1 (en) * 1995-03-13 1996-09-19 University Of South Florida Sertoli cells as transplantation facilitator for cell transplantation
US5702700A (en) * 1995-03-13 1997-12-30 University Of South Florida Sertoli cells as neurorecovery inducing cells for Parkinson's disease
WO1996033264A1 (en) * 1995-04-20 1996-10-24 University Of South Florida Purified and isolated sertoli cell aggregate
US6037175A (en) * 1996-03-12 2000-03-14 The University Of South Florida Method and media for enhancing cryopreservation of cells
JP2002500202A (ja) * 1998-01-02 2002-01-08 タイタン ファーマシューティカルズ， インコーポレイテッド 免疫優位部位の生成のための色素性網膜上皮細胞の使用
ES2338076T3 (es) * 1998-11-06 2010-05-03 Sertoli Technologies, Inc. Produccion de un factor biologico y creacion de un entorno inmunologicamente privilegiado usando celulas de sertoli alteradas geneticamente.
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
CA2355675C (en) * 1998-12-15 2006-07-04 Universidad Nacional Autonoma De Mexico Process and device for facilitating the implantation of biological material
US6303355B1 (en) 1999-03-22 2001-10-16 Duke University Method of culturing, cryopreserving and encapsulating pancreatic islet cells
US6365385B1 (en) 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
US7115256B1 (en) 1999-04-09 2006-10-03 Titan Pharmaceuticals, Inc. Methods of treating schizophrenia
ES2272482T3 (es) 2000-01-20 2007-05-01 Diabcell Pty Limited Preparacion y xenotransplante de islotes porcinos.
US6790441B1 (en) 2000-06-13 2004-09-14 University Of South Florida Sertoli cells as biochambers
WO2002024107A2 (en) 2000-09-20 2002-03-28 Islet Sheet Medical Llc Fabrication of thin sheet bio-artificial organs
KR20030096381A (ko) * 2001-05-11 2003-12-24 오쏘-맥네일 파머슈티칼 인코퍼레이티드 동물에 사용하기 위한 면역 조절장치
WO2003027270A1 (en) * 2001-09-28 2003-04-03 Diabcell Pty Limited Growing xenotransplant material in culture
CA2476832A1 (en) * 2002-02-22 2003-08-28 Prophy Med Ab Use of an inhibitor or antagonist against tissue factor
US20040062753A1 (en) * 2002-09-27 2004-04-01 Alireza Rezania Composite scaffolds seeded with mammalian cells
CN1791670A (zh) * 2003-06-24 2006-06-21 戴伯塞尔有限公司 用于异种移植的用猪支持细胞培养的猪胰岛
US20050118145A1 (en) * 2003-07-03 2005-06-02 Jannette Dufour Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
WO2006118564A2 (en) * 2004-04-29 2006-11-09 Washington State University Research Foundation MODIFIED CELLS EXPRESSING A PROTEIN THAT MODULATES ACTIVITY OF bHLH PROTEINS, AND USES THEREOF
KR20070085223A (ko) 2004-07-29 2007-08-27 유니버시티 오브 마이애미 세포 치료를 위한 하이브리드 장치
US20070065422A1 (en) * 2005-09-20 2007-03-22 Cameron Don F Induction of immune tolerance by sertoli cells
WO2007089572A2 (en) * 2006-01-26 2007-08-09 John Constance M Proliferative primary human sertoli cell cultures and their applications
AU2007278850B2 (en) * 2006-07-28 2013-06-06 Sertocell Biotechnology (Us) Corp. Adult sertoli cells and uses thereof
WO2009105278A2 (en) 2008-02-21 2009-08-27 University Of South Florida Nanoparticle targeted drug delivery to the lungs using extra-testicular sertoli cells
US8709400B2 (en) * 2009-07-27 2014-04-29 Washington University Inducement of organogenetic tolerance for pancreatic xenotransplant
EA025142B1 (ru) 2009-08-28 2016-11-30 Сернова Корпорэйнш Способ и устройство для клеточной трансплантации
MX2010013135A (es) 2010-11-30 2012-05-31 Val De Bio S De R L De C V Procedimiento y dispositivo mejorados para favorecer el trasplante de material biológico.
US10532128B2 (en) 2015-11-18 2020-01-14 Viera Bioscience, Inc. Implantable cellular therapy device for treatment of graft versus host disease and tolerance induction
CA3116829A1 (en) 2017-10-17 2019-04-25 The Methodist Hospital System Delivery devices
US20220211770A1 (en) 2019-05-01 2022-07-07 Sernova Corporation Methods of treating diabetes using devices for cellular transplantation
US20240287464A1 (en) * 2021-06-30 2024-08-29 Polbionica Sp. Z O.O. A medium for storing isolated pancreatic islets and a method for storing isolated pancreatic islets

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158874A (en) * 1985-08-30 1992-10-27 The United States Of America As Represented By The Department Of Health And Human Services Determining metastic potential of tumor cells and isolating metastic tumor cells
US4829000A (en) * 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
US5053332A (en) * 1989-07-24 1991-10-01 Cook Richard B Agarose beads, preferably incorporating biological materials
US5304603A (en) * 1991-06-18 1994-04-19 The Population Council Leydig cell stimulator
DE4227066A1 (de) * 1992-08-16 1994-02-17 Bernhard Josef Dr Med Hering Langerhans'sche Inseln in reiner Form
US5474905A (en) * 1993-11-24 1995-12-12 Research Corporation Technologies Antibodies specific for streptococcus pneumoniae hemin/hemoglobin-binding antigens
US5849285A (en) * 1994-04-13 1998-12-15 Research Corporation Technologies, Inc. Autoimmune disease treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells

Also Published As

Publication number Publication date
FI120696B (fi) 2010-01-29
FI20085733L (fi) 2008-07-18
EP0755258B1 (en) 2002-01-23
CA2187803C (en) 1999-09-28
US5725854A (en) 1998-03-10
DE69525151D1 (de) 2002-03-14
JPH09512015A (ja) 1997-12-02
CA2187803A1 (en) 1995-10-26
NO320713B1 (no) 2006-01-23
NO964342D0 (no) 1996-10-11
FI120670B (fi) 2010-01-29
EP0755258A1 (en) 1997-01-29
US5759534A (en) 1998-06-02
AU715177B2 (en) 2000-01-20
AU2289395A (en) 1995-11-10
DE69525151T2 (de) 2002-08-14
FI964033A0 (fi) 1996-10-08
FI964033L (fi) 1996-12-12
DK0755258T3 (da) 2002-05-13
ES2169128T3 (es) 2002-07-01
ATE212230T1 (de) 2002-02-15
US5843430A (en) 1998-12-01
WO1995028167A1 (en) 1995-10-26

Similar Documents

Publication Publication Date Title
NO964342D0 (no) Fremgangsmåter for behandling av sykdom under anvendelse av Sertoli-celler og allografter eller zenografter
BR9710689A (pt) Processo para tratar diarr-ia aguda e para proporcionar terapia a um mam¡fero tendo diarr-ia e prepara-Æo terap-utica para redu-Æo de sintomas de diarr-ia
DK0918848T3 (da) Fremgangsmåder til at behandle kræftsygdomme og patogene infektioner ved anvendelse af antigenpræsenterende celler påfyldt med RNA
HRP960508B1 (en) A method of enhancing cellular production of molecular chaperon,hydroxalamine derivatives useful for enhancing the chaperon production and the preparation thereof
MD1444B2 (ro) Metode de inducere a toleranţei celulelor T faţă de un transplant de organe sau ţesuturi
NO960711L (no) Neural regenerering ved anvendelse av humane ben-morfogneiske proteiner
DK1526172T3 (da) Fremgangsmåde til replikation af influenzavira i cellekultur og ved fremgangsmåden opnåelige influenzavira
DE69527521D1 (de) Behandlung von biologischen materialen vor der fixierung
ES2169299T3 (es) Procedimiento para la destruccion de celulas tumorales contaminantes en transplantes de celulas madre utilizando anticuerpos especificos.
DK0702563T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme
WO1996012794A3 (en) Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
CA2346644A1 (en) Method for preventing xenograft transplant rejection using photodynamic therapy
NO951240L (no) Anvendelse av IL-10 til forebyggelse eller behandling av insulinavhengig diabetes mellitus
DE59002154D1 (de) Kombinationspraeparate enthaltend rifampicin und thioacetazon sowie gegebenenfalls isonicotinsaeurehydrazid oder ethambutol als aktive wirkstoffe.
DE60037876D1 (de) Verfahren zur Herstellung von entwickelten und unentwickelten Pankreasendokrinezellen, Zellpräparat und Verwendung davon zur Behandlung von Diabetes
DK0883406T3 (da) Anvendelse af IL-7 til behandling af autoimmune sygdomme og især insulinafhængig diabe-tesmellitus i særdeleshed
TW200507875A (en) Remedy for diabetes
DK1128837T3 (da) Medikament til at foebygge og bevirke tilbagegang af atherosclerose hos pattedyr
TR199802706T2 (xx) Bir bitki hastal���n�n iyile�tirilmesi i�in y�ntem.
NO20012214L (no) Fremstilling av en biologisk faktor og frembringelse av et immunologisk fordelaktig miljö ved anvendelse av genetiskforandrede Sertoliceller
Shepanek et al. In vitro cell changes in laser-exposed tissue
ES2072331T3 (es) Procedimiento para la descontaminacion de cultivos celulares que contienen micoplasmas.
ATE22534T1 (de) Ruscusextrakt, verfahren zur herstellung und dessen verwendung als venetonisches aktives mittel.
GEP19970991B (en) Method for Decay of Tumor Cells with Mammalia and Pharmacentical Composition for this Purpose

Legal Events

Date Code Title Description
MK1K Patent expired